Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
A.M. Di Bisceglie, R.L. Carithers, G.J. Gores.
Hepatocellular carcinoma.
Hepatology, 28 (1998), pp. 1161-1165
[2.]
Y. Yamashita, M. Takahashi, Y. Baba, S. Kanazawa, C. Charnsangavej, D. Yang, et al.
Hepatocellular carcinoma with or without cirrhosis: a comparison of CT and angiographic presentations in the United States and Japan.
Abdom Imaging, 18 (1993), pp. 168-175
[3.]
M.F. Yuen, C.C. Cheng, I.J. Lauder, S.K. Lam, C.G. Ooi, C.L. Lai.
Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.
Hepatology, 31 (2000), pp. 330-335
[4.]
M.J. Tong, L.M. Blatt, V.W. Kao.
Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.
J Gastroenterol Hepatol, 16 (2001), pp. 553-559
[5.]
J.F. Tsai, J.E. Jeng, L.Y. Chuang, W.Y. Chang, M.Y. Hsieh, Z.Y. Lin, et al.
Urinary transforminf groth factor-beta1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Scand J Gastroenterol, 32 (1997), pp. 254-260
[6.]
M.F. Yuen, S. Norris, L.W. Evans, P.G. Langley, R.D. Hughes.
Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis.
Scand J Gastroenterol, 37 (2002), pp. 233-238
[7.]
D. Kardum, J. Huskic, D. Fabijanic, M. Banic, M. Buljevac, M. Kujundzic, et al.
Activity of serum angiotensin-converting enzyme as a tumor marker of hepatocellular carcinoma.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1209-1213
[8.]
T. Stroffolini, P. Andreone, A. Andriulli, A. Ascione, A. Craxi, M. Chiaramonte, et al.
Gross pathologic types of hepatocellular carcinoma in Italy.
Oncology, 56 (1999), pp. 189-192
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
